CAS Number99614-02-5
SynonymsONDANSETRON HYDROCHLORIDE DIHYDRATE; 9-Methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; GR 38032F; 9-METHYL-3-[(2-METHYL-1H-IMIDAZOLYL)METHYL]-1,2,3,9-TETRAHYDRO-4H-CARBAZOLE-4-ONE; 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one; ONDANSETRON-D5; ONDANSETRON HCL D6; 9-METHYL-3-(2-METHYL-1H-IMIDAZOLYL)-METHYL-1,2,3,9-TETRAHYDRO-4H-CARBAZOLE-4-ONE; Zofran; ONDANSETRONBASE; R(+)-Ondansetron; Ondansetro; ONDANSETRON HYDROCHLORIDE; 9-METHYL-3-[(2-METHYL-1H-IMIDAZOLYL)-METHYL]-1,2,3,9-TETRAHYDRO-4H-CARBAZOLE-4-ONE; GR 38032X; ONDANESTRON; GR-38032F; MFCD00764297; Ondansetron; ONDANSETRON HCL; EINECS 619-449-4
Molecular FormulaC18H19N3O
Molecular Weight293.36
Purity99%
Density1.3±0.1 g/cm3
Boiling Point546.0±30.0 °C at 760 mmHg
Melting Point231 - 232ºC
AppearanceWhite to yellow crystals
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 99614-02-5 |
| Catalog No. | 2A-9011772 |
| Chinese Name | 昂丹司琼 |
| Synonyms | ONDANSETRON HYDROCHLORIDE DIHYDRATE; 9-Methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; GR 38032F; 9-METHYL-3-[(2-METHYL-1H-IMIDAZOLYL)METHYL]-1,2,3,9-TETRAHYDRO-4H-CARBAZOLE-4-ONE; 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one; ONDANSETRON-D5; ONDANSETRON HCL D6; 9-METHYL-3-(2-METHYL-1H-IMIDAZOLYL)-METHYL-1,2,3,9-TETRAHYDRO-4H-CARBAZOLE-4-ONE; Zofran; ONDANSETRONBASE; R(+)-Ondansetron; Ondansetro; ONDANSETRON HYDROCHLORIDE; 9-METHYL-3-[(2-METHYL-1H-IMIDAZOLYL)-METHYL]-1,2,3,9-TETRAHYDRO-4H-CARBAZOLE-4-ONE; GR 38032X; ONDANESTRON; GR-38032F; MFCD00764297; Ondansetron; ONDANSETRON HCL; EINECS 619-449-4 |
| Molecular Formula | C18H19N3O |
| Molecular Weight | 293.36 |
| Purity | 99 |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 546.0±30.0 °C at 760 mmHg |
| Melting Point | 231 - 232ºC |
| Appearance | White to yellow crystals |
| Water Solubility | H2O: >5 mg/mL |
| Storage Condition | −20°C |
| Application | Ondansetron (GR38032) is a 5-HT3 receptor antagonist. |
| HTC | 2933990090 |
| MDL Number | MFCD00833882 |
| SMILES | [n]4(c(ncc4)C)CC1CCc2[n](c3c(c2C1=O)cccc3)C |
| InChI | 1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3 |
| InChI Key | FELGMEQIXOGIFQ-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/11772_1_99614_02_5.pdf |
| Bioactivity | Ondansetron(GR38032) is a serotonin 5-HT3 receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.IC50 Value: Target: 5- HT3 Receptorin vitro: 5-HT evoked transient inward currents (EC50 = 3.4 microM; Hill coefficient = 1.8) that were blocked by the 5-HT3 receptor antagonist ondansetron (IC50 = 103 pM) [1]. The 5-HT3A receptor antagonist ondansetron (0.3 nM) reversibly inhibited the 5-HT (30 microM) signal by 70% and at 3 nM it abolished the response [2].in vivo: Acute ondansetron administration at the lowest dose (0.1 mg/kg, IP) tested had no effect, while other doses (0.33 and 1 mg/kg, IP) produced improvements in auditory gating [3]. Different doses of ondansetron were injected intraperitoneally (i.p.) at fixed times during the day to determine both the sublethal (TD50) and lethal (LD50) doses, which were, respectively, 3.7 ± 0.6 mg/kg and 4.6 ± 0.5 mg/kg [4]. ondansetron (0.25-1.0 mg/kg, subcutaneously) given before the challenge dose of ethanol (2.4 g/kg, intraperitoneally) injection, significantly and dose dependently attenuated the expression of sensitization. In addition, ondansetron (1.0 mg/kg, subcutaneously) given before ethanol injection on days 1, 4, 7, and 10 significantly blocked the development (days 1, 4, 7, and 10), and expression (day 15) of sensitization to the locomotor stimulant effect of ethanol injection [5]. Toxicity: Ondansetron may be safe in lower doses used to prevent nausea and vomiting in radiation treatment or postoperatively. However, as there is a report that a lower dose of ondansetron prolonged the QT interval in healthy volunteers, this needs to be clarified by the FDA [6]. Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Research Areas >> Neurological Disease References [1]. Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65. [2]. Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):255-65. [3]. Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50. [4]. Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16. [5]. Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83. [6]. Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Boiling Point 546.0±30.0 °C at 760 mmHg Melting Point 231 - 232ºC Molecular Formula C18H19N3O Molecular Weight 293.363 Flash Point 284.0±24.6 °C Exact Mass 293.152802 PSA 39.82000 LogP 2.07 Vapour Pressure 0.0±1.5 mmHg at 25°C Index of Refraction 1.678 InChIKey FELGMEQIXOGIFQ-UHFFFAOYSA-N SMILES Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O Storage condition −20°C Water Solubility H2O: >5 mg/mL |
| Use of | Properties Name 9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-2,3-dihydro-1H-carbazol-4(9H)-one Synonym More Synonyms Ondansetron Biological Activity Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Research Areas >> Neurological Disease References [1]. Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65. [4]. Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16. [5]. Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83. [6]. Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31. Chemical & Physical Properties Molecular Formula C18H19N3O Exact Mass 293.152802 PSA 39.82000 Index of Refraction 1.678 InChIKey FELGMEQIXOGIFQ-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Ofloxacin | 82419-36-1 | 2A-9011747 |
| Olmesartan | 144689-24-7 | 2A-9011758 |
| Olmesartan medoxomil | 144689-63-4 | 2A-9011759 |
| Olsalazine | 15722-48-2 | 2A-9011765 |
| Omeprazole sulfone | 2A-302851 | 2A-9011768 |
| Ondansetron hydrochloride | 99614-01-4 | 2A-9011773 |
| Ondansetron hydrochloride dihydrate | 103639-04-9 | 2A-9011774 |
| Ornidazole | 16773-42-5 | 2A-9011790 |
| Oseltamivir | 196618-13-0 | 2A-9011797 |
| Oseltamivir ac | 2A-302881 | 2A-9011798 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS